Why Corcept Therapeutics (CORT) Is Plummeting Today

NEW YORK (TheStreet) -- Corcept Therapeutics  (CORT) plummeted Wednesday after the company stopped a late-stage trial of its depression treatment drug Mifepristone after analysis determined it was unlikely to succeed.

Data analysis from the first 226 patients enrolled in the trial determined the drug did not significantly reduce psychotic depression symptoms. An independent safety committee analyzed the data and suggested stopping the trial because it was unlikely to produce positive results.

Corcept announced it would halt the trial to shift its focus to other, potentially more fruitful programs, especially in oncology.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 47.26% to $2.12 at 12:01 p.m.

CORT Chart

CORT data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers